Bone-biomarkers of Spinal Cord Injury Patients

Completed

• Conditions: Osteoporosis; Spinal Cord Injuries; Bone Resorption

• Registration Number: NCT04403256
• Lead Sponsor: Yeungnam University Hospital

Brief Summary

Patients with spinal cord injury have a high prevalence of osteoporosis due to chronic skeletal unloading. Recently, various treatment drugs for osteoporosis have been developed. In particular, romosozumab, a sclerostin inhibitor, has been reported to have a high therapeutic effect as an inhibitor of bone resorption while promoting bone formation. However, there are a few research concerning sclerostin of spinal cord injuries patients. Therefore we want to analyze the change of sclerostin as well as factors indicating bone formation and absorption marker in spinal cord injury patient.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-02-05
• Study First Submitted: 2020-03-25
• Study First Submitted QC: 2020-05-25
• Study First Posted: 2020-05-27
• Status Verified: 2021-08
• Primary Completion: 2021-08-30
• Study Completion: 2021-08-30
• Last Update Submitted: 2021-08-30
• Last Update Posted: 2021-08-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

• spinal cord injury patients
• Functional ambulatory category index of 3 or less

Exclusion Criteria

• history of using bone absorption medication within the effective period

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum sclerostin level	1 year	Serum sclerostin level in spinal cord injury patients

Trial Locations

Locations (1)

Yeungnam University Hospital; 🇰🇷 Daegu, Korea, Republic of